NUS MEDICINE AND 22HEALTH VENTURES ANNOUNCE JOINT HEALTHTECH ACCELERATOR

(SINGAPORE, 1 JULY 2024) - **The Yong Loo Lin School of Medicine, National University of Singapore** ("**NUS Medicine**"), and **22Health Ventures**, an early-stage healthtech investment firm ("**22Health**"), announce their joint accelerator programme, *NUS Medicine Digital Advanced Technology Accelerator (DATA), an NUS Medicine – 22Health Ventures partnership* (the "**Accelerator**"). Applications open today for the first cohort of early-stage start-up participants in the Accelerator, with the 11-week programme for the cohort launching in late-September 2024. Further details may be found at https://medicine.nus.edu.sg/digital-accelerator/.

The objective of the Accelerator is to promote the development of promising ideas in digital healthcare and translate these into thriving businesses that elevate personal health and well-being. The current scope of the Accelerator involves identifying and developing companies focused on digital health from Singapore and across Southeast Asia. NUS Medicine and 22Health Ventures are aligned on accelerating healthtech successes through digital empowerment, market access to achieve global competitiveness and opportunities for funding.

As Singapore's first and largest medical school, **NUS Medicine** is uniquely positioned in Singapore to develop an ecosystem of healthcare professionals, software engineers and entrepreneurs to innovate technologies, while **22Health Ventures** offers international expertise, value-add services and early-stage funding to accelerate U.S. market access and position startups for success.

Prof Chong Yap Seng, Dean of NUS Medicine, said, "Digital health innovation is the future of medicine. Artificial intelligence and digital technologies will create the next medical breakthrough and catalyse the growth of new therapeutics, treatments and vaccines. The NUS Medicine Digital Advanced Technology Accelerator (DATA) aims to encourage the growth of promising ideas in digital healthcare, bring them to fruition and make an impact on global healthcare. By partnering with 22Health, we aim to foster and support a culture of continuous healthtech innovation and enable a thriving digital healthcare ecosystem. The Accelerator is expected to have a significant and sustainable impact on the Singapore innovation community, and we are proud to be a leader in this objective."

The Accelerator is focused on:

■   sourcing Singapore and Southeast Asian startups, including through hack-a-thons (such as NUS Medicine HealthHack)

■   engaging with participants, in formal and informal sessions, over a 11-week period to allow entrepreneurs needed time to study, learn and evolve

■   offering workshops and other programmes across a wide range of components, including global entrepreneurship and business building skills, intellectual property, fundraising, business and financial models, market education and legal and regulatory matters

- making introductions to clinicians, payor experts and other industry professionals for problem-solution fit, clinical validation and market viability in Singapore and the U.S.

- presenting proprietary content modules with a primary focus on innovating into the U.S. health market

- providing guidance on company and product roadmaps with milestones and timelines

- arranging and overseeing ongoing, multi-faceted mentorship leveraging a strong U.S. network to enhance founder development and enable global competitiveness

- hosting weekly "office hours" with access to expert guidance

- awarding launch capital to accelerator participants with the opportunity to earn full funding in one or more later rounds

- sponsoring community-facing activities, such as seminars and conferences

Paul Scibetta, Co-Founder & Managing Partner of 22Health, said, "At 22Health, we believe that investing in transformative healthtech companies is increasingly important for global health. The Accelerator is well-positioned to accelerate the transition to next-generation health and care and thereby to improve health and wellness for all people." Mr. Scibetta added, "22Health is proud to collaborate with NUS Medicine. We appreciate that the leading scientific and technology research and academic capabilities of our partner will provide early-stage support and clinical validation to enable Singapore's entrepreneurs to reach increasing levels of global competitiveness".

*   *   *   *   *

For media enquiries, please contact:

Gladys SIM
Senior Assistant Manager, Communications
Yong Loo Lin School of Medicine
National University of Singapore
DID: +65 9007 1322
Email: gladyssim@nus.edu.sg

About National University of Singapore (NUS)

The National University of Singapore (NUS) is Singapore's flagship university, which offers a global approach to education, research and entrepreneurship, with a focus on Asian perspectives and expertise. We have 16 colleges, faculties and schools across three campuses in Singapore, with more than 40,000 students from 100 countries enriching our vibrant and diverse campus community. We have also established more than 20 NUS Overseas Colleges entrepreneurial hubs around the world.

Our multidisciplinary and real-world approach to education, research and entrepreneurship enables us to work closely with industry, governments and academia to address crucial and complex issues relevant to Asia and the world. Researchers in our faculties, research centres of excellence, corporate labs and more than 30 university-level research institutes focus on themes that include energy; environmental and urban sustainability; treatment and prevention of diseases; active ageing; advanced materials; risk management and resilience of financial systems; Asian studies; and Smart Nation capabilities such as artificial intelligence, data science, operations research and cybersecurity.

For more information on NUS, please visit http://www.nus.edu.sg/

About the NUS Yong Loo Lin School of Medicine (NUS Medicine)

The NUS Yong Loo Lin School of Medicine is Singapore's first and largest medical school. Our enduring mission centres on nurturing highly competent, values-driven and inspired healthcare professionals to transform the practice of medicine and improve health around the world.

Through a dynamic and future-oriented five-year curriculum that is inter-disciplinary and inter-professional in nature, our students undergo a holistic learning experience that exposes them to multiple facets of healthcare and prepares them to become visionary leaders and compassionate doctors and nurses of tomorrow. Since the School's founding in 1905, more than 12,000 graduates have passed through our doors.

In our pursuit of health for all, our strategic research programmes focus on innovative, cutting-edge biomedical research with collaborators around the world to deliver high impact solutions to benefit human lives.

The School is the oldest institution of higher learning in the National University of Singapore and a founding institutional member of the National University Health System. It is one of the leading medical schools in Asia and ranks among the best in the world (Times Higher Education World University Rankings 2024 by subject and the Quacquarelli Symonds (QS) World University Rankings by subject 2023).

For more information about NUS Medicine, please visit https://medicine.nus.edu.sg/

About 22Health Ventures

22Health Ventures is an early-stage healthtech venture firm, led by proven entrepreneurs, deeply embedded in Singapore and providing accelerated access to the U.S. health market, with the goal of empowering healthtech startups to compete globally. 22Health Ventures provides both capital

and value-add services to portfolio companies focused on precision medicine, digital modalities and healthy ageing. For more details, see *https://www.22healthventures.com*.